{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:26:47Z","timestamp":1787498807006,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["2021P002772"],"award-info":[{"award-number":["2021P002772"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.msard.2023.105345","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T22:53:52Z","timestamp":1701989632000},"page":"105345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Ocrelizumab in highly disabled progressive multiple sclerosis patients"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6077-0654","authenticated-orcid":false,"given":"Maria","family":"Houtchens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6802-1567","authenticated-orcid":false,"given":"Danielle","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.105345_bib0001","unstructured":"www.nationalmssociety.org\/Treating-MS\/Medications. [cited 2022 11\/20],2022."},{"issue":"10","key":"10.1016\/j.msard.2023.105345_bib0002","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1093\/brain\/awaa251","article-title":"Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis","volume":"143","author":"Amato","year":"2020","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.msard.2023.105345_bib0003","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/ene.14824","article-title":"Risk of requiring a wheelchair in primary progressive multiple sclerosis: data from the ORATORIO trial and the MSBase registry","volume":"29","author":"Butzkueven","year":"2022","journal-title":"Eur. J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2023.105345_bib0004","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s13311-021-01104-8","article-title":"Predictors of ocrelizumab effectiveness in patients with multiple sclerosis","volume":"18","author":"Cellerino","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"9","key":"10.1016\/j.msard.2023.105345_bib0005","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1007\/s00415-022-11114-x","article-title":"Neurophysiological and behavioural correlates of ocrelizumab therapy on manual dexterity in patients with primary progressive multiple sclerosis","volume":"269","author":"Dubbioso","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.105345_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103171","article-title":"Evaluation of ocrelizumab in older progressive multiple sclerosis patients","volume":"55","author":"Epstein","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2023.105345_bib0007","doi-asserted-by":"crossref","first-page":"545","DOI":"10.5014\/ajot.55.5.545","article-title":"Describing and predicting the possession of assistive devices among persons with multiple sclerosis","volume":"55","author":"Finlayson","year":"2001","journal-title":"Am. J. Occup. Ther."},{"key":"10.1016\/j.msard.2023.105345_bib0008","unstructured":"Jill S. Fischer, e.a. Multiple sclerosis functional composite (MSFC) administration and scoring manual. 2001. 6\u20138."},{"issue":"14","key":"10.1016\/j.msard.2023.105345_bib0009","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1177\/1352458518808189","article-title":"Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: findings from the phase III randomized ORATORIO trial","volume":"24","author":"Fox","year":"2018","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2023.105345_bib0010","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/ene.14823","article-title":"Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials","volume":"29","author":"Giovannoni","year":"2022","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2023.105345_bib0011","article-title":"The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis","volume":"7","author":"Glanz","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"9350","key":"10.1016\/j.msard.2023.105345_bib0012","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial","volume":"360","author":"Hartung","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2023.105345_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102492","article-title":"Shorter infusion time of ocrelizumab: results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis","volume":"46","author":"Hartung","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2023.105345_bib0014","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.msard.2023.105345_bib0015","doi-asserted-by":"crossref","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","article-title":"Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension","volume":"95","author":"Hauser","year":"2020","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/j.msard.2023.105345_bib0016","doi-asserted-by":"crossref","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2023.105345_bib0017","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2023.105345_bib0018","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s00115-021-01080-6","article-title":"[Disease-modifying treatment of secondary progressive multiple sclerosis]","volume":"92","author":"Hoffmann","year":"2021","journal-title":"Nervenarzt"},{"issue":"10127","key":"10.1016\/j.msard.2023.105345_bib0019","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.msard.2023.105345_bib0020","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1177\/1352458517694432","article-title":"New insights into the burden and costs of multiple sclerosis in Europe","volume":"23","author":"Kobelt","year":"2017","journal-title":"Mult. Scler."},{"issue":"11","key":"10.1016\/j.msard.2023.105345_bib0021","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.msard.2023.105345_bib0022","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s00415-019-09395-w","article-title":"Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis","volume":"267","author":"Li","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.105345_bib0023","unstructured":"Marsh, D.E.S., November 19). Severity of adverse drug reactions \u2013 drugs. Merck manuals consumer version. Retrieved November 22, 2022, from www.merckmanuals.com\/home\/drugs\/adverse-drug-reactions\/severity-of-adverse-drug-reactions."},{"issue":"3","key":"10.1016\/j.msard.2023.105345_bib0024","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2023.105345_bib0025","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2023.105345_bib0026","doi-asserted-by":"crossref","first-page":"e477","DOI":"10.1212\/NXI.0000000000000477","article-title":"Cladribine tablets added to IFN-\u03b2 in active relapsing MS: the ONWARD study","volume":"5","author":"Montalban","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2023.105345_bib0027","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40120-020-00224-1","article-title":"Work productivity outcomes associated with ocrelizumab compared with other disease-modifying therapies for multiple sclerosis","volume":"10","author":"Neuberger","year":"2021","journal-title":"Neurol. Ther."},{"issue":"6","key":"10.1016\/j.msard.2023.105345_bib0028","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2217\/nmt-2019-0024","article-title":"Diagnosis and management of secondary-progressive multiple sclerosis: time for change","volume":"9","author":"Oh","year":"2019","journal-title":"Neurodegen. Dis. Manag."},{"issue":"3","key":"10.1016\/j.msard.2023.105345_bib0029","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/WCO.0000000000000701","article-title":"Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis","volume":"32","author":"Schweitzer","year":"2019","journal-title":"Curr. Opin. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2023.105345_bib0030","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1007\/s10072-022-06197-3","article-title":"Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis","volume":"43","author":"\u015aladowska","year":"2022","journal-title":"Neurol. Sci."},{"issue":"3","key":"10.1016\/j.msard.2023.105345_bib0031","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1682\/JRRD.2009.07.0096","article-title":"Multiple sclerosis and mobility-related assistive technology: systematic review of literature","volume":"47","author":"Souza","year":"2010","journal-title":"J. Rehabil. Res. Dev."},{"issue":"5","key":"10.1016\/j.msard.2023.105345_bib0032","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s00415-019-09248-6","article-title":"Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis","volume":"266","author":"Turner","year":"2019","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2023.105345_bib0033","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1055\/s-2008-1040881","article-title":"The natural history of multiple sclerosis: update 1998","volume":"18","author":"Weinshenker","year":"1998","journal-title":"Semin. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2023.105345_bib0034","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/ana.25313","article-title":"Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial","volume":"84","author":"Wolinsky","year":"2018","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2023.105345_bib0035","article-title":"An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability","volume":"6","author":"Wolinsky","year":"2020","journal-title":"Mult. Scler. J. Exp. Transl. Clin."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823008465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823008465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:10:25Z","timestamp":1761901825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823008465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":35,"alternative-id":["S2211034823008465"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.105345","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocrelizumab in highly disabled progressive multiple sclerosis patients","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.105345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105345"}}